DataMeds AI, Inc.
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
About DataMeds AI
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Wellgistics Health, Inc. operates as a healthcare and pharmaceutical holding company providing integrated solutions across dispensing, delivery, care coordination, and clinical management. Its business model spans three primary operating segments: a retail specialty pharmacy, pharmaceutical wholesale operations, and a technology division. The company's offerings include distribution of specialty-lite and maintenance medications, clinical concierge support, and digital prescription transfer services. Wellgistics serves individual patients, independent pharmacies, healthcare providers, pharmaceutical manufacturers, and health payors.
The company operates through wholly owned operating subsidiaries, including Wellgistics, LLC and Wood Sage LLC, distributing niche pharmaceuticals to a nationwide network of independent pharmacy partners across the United States. Its retail pharmacy operations originate from a facility established in Florida. Wellgistics Health maintains its principal executive offices in Tampa, Florida.
Summary of the business section of DataMeds AI's latest annual report, written by StockData.
Company profile
Company
- Legal name
- DataMeds AI, Inc.
- Founded
- 2022
- Headquarters
- Tampa, FL
- Address
- 3000 Bayport Drive Suite 950 33607
- Phone
- 1-843-302-1785
- Employees
- 35, Dec 31, 2025
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Suri & Co., Chartered Accountants, Bengaluru, India
Stock & identifiers
- Ticker
- MEDS
- Exchange
- Nasdaq
- IPO date
- Feb 21, 2025
- Shares outstanding
- 3M, Aug 17, 2026
- Public float
- $27.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Aug 17, 2026; 1-for-50 reverse, May 26, 2026
- SEC CIK
- 2030763
- CUSIP
- 949503205
- ISIN
- US9495032057
- EIN
- 93-3264234
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Prashant Patel | Chief Executive Officer, Director | 9,354,365 |
| Srinivas Kalla | Chief Information Officer | 293,333 |
| Mark DiSiena | Chief Financial Officer | – |
| Brian Norton | Chief Executive Officer | 11,524,308 |
| Nikul Panchal | Chief Pharmacy Officer | 375,761 |
| Shafaat Pirani | Chief Clinical Officer | 102,080 |
| Surendra K. Ajjarapu | Director | 15,445,447 |
| Gary L. Herman | Director | – |
| Eric Michael Sherb | Director | – |
| Marlene Velez | Director | – |
| Howard A. Doss | Director | – |
| Donald G. Fell | Director | – |
| Steven Dale Lee | Director | – |
| Michael L. Peterson | Director | 200,000 |
| Donald William Anderson | Director | 244,720 |
| Rebecca M. Shanahan | Director | 244,720 |
| Sajid Syed | Director | 244,720 |
Employees
Headcount reported in annual reports
“● loss of key employees of the acquired businesses following the acquisition; and … 35”
Corporate history
Events identified from SEC filings